

Supplementary Table 1: Non-small cell lung cancer cell lines used to develop the sorafenib sensitivity signature

Sort	Cell Line	KRAS	EGFR	Sorafenib (uM)
1	H1703	WT	WT	-0.85
2	H2009	[c.35G>C; p.G12A]	WT	-0.71
3	H2405	WT	WT	-0.24
4	HCC1833	WT	WT	-0.12
5	HCC2429	WT	WT	-0.02
6	H1693	WT	WT	0.02
7	H2087	WT	WT	0.08
8	H2073	WT	WT	0.10
9	H1755	WT	WT	0.11
10	H2882	WT	WT	0.13
11	EKVX	WT	WT	0.14
12	HCC1195	WT	WT	0.19
13	H2342	WT	WT	0.20
14	H522	WT	WT	0.21
15	HCC4018	WT	WT	0.24
16	H1395	WT	WT	0.24
17	H226	WT	WT	0.30
18	HCC4019	[c.35G>T; p.G12V]	WT	0.33
19	Calu-6	[c.180_181TC>CA; p.Q61K]	WT	0.33
20	H1770	WT	WT	0.35
21	H920	WT	WT	0.42
22	H1437	WT	WT	0.43
23	HCC461	12GAT (Gazdar)	WT	0.44
24	H23	[c.34G>T; p.G12C]	WT	0.44
25	H157	[c.34G>C; p.G12R]	WT	0.45
26	H2228	WT	WT	0.45
27	H322	WT	WT	0.46
28	H1155	[c.183A>T; p.Q61H]	WT	0.48
29	SK-LU-1	[c.35G>A; p.G12D]	WT	0.48
30	H2122	[c.34G>T; p.G12C]	WT	0.49
31	A549	[c.34G>A; p.G12S]	WT	0.52
32	HCC1359	WT	WT	0.52
33	H358	[c.35G>T; p.G12V]	WT	0.52
34	HCC95	WT	WT	0.52
35	HCC515	[c.38G>A; p.G13D]	WT	0.52
36	HCC44	[c.34G>T; p.G12C]	WT	0.53
37	H1299	WT	WT	0.53
38	H1568	WT	WT	0.54
39	H650	[c.182A>T; p.Q61L]	WT	0.54

40	H1993	WT	WT	0.55
41	H2126	WT	WT	0.55
42	HCC193	WT	WT	0.55
43	H460	[c.183A>T; p.Q61H]	WT	0.57
44	Calu-1	[c.34G>T; p.G12C]	WT	0.57
45	H1838	WT	WT	0.61
46	HCC15	WT	WT	0.61
47	H1355	[c.37G>T; p.G13C]	WT	0.64
48	H2887	[c.35G>T; p.G12V]	WT	0.64
49	H324	WT	WT	0.65
50	H2170	WT	WT	0.66
51	HCC4017	[c.35G>T; p.G12V]	WT	0.67
52	Calu-3	WT	WT	0.67
53	H1734	[c.37G>T; p.G13C]	WT	0.68
54	H661	WT	WT	0.68
55	H1819	WT	WT	0.68
56	HCC366	WT	WT	0.71
57	HCC78	WT	WT	0.71
58	H2347	WT	WT	0.72
59	H1666	WT	WT	0.73
60	HOP-62	[c.34G>T; p.G12C]	WT	0.75
61	H1648	WT	WT	0.76
62	H2291	[c.34_35GG>TT; p.G12F]	WT	0.81
63	H441	[c.35G>T; p.G12V]	WT	0.82
64	H82	WT	WT	0.82
65	H1373	[c.34G>T; p.G12C]	WT	0.89
66	H1792	[c.34G>T; p.G12C]	WT	0.89
67	H1781	WT	WT	0.93
68	HCC1171	[c.35G>T; p.G12V]	WT	0.95